Donate

News

Illustration for article: International Rare Disease Day: See you on February 28th

International Rare Disease Day: See you on February 28th

A rare disease affects nearly 30 million people in Europe and 3 million in France. On February 28th, more than 60 countries will be mobilised around a single message: "Rare Disorders without Borders."
Illustration for article: The AFM-Telethon reinforces its Scientific Council

The AFM-Telethon reinforces its Scientific Council

There has been a 42% increase in new members of the 7th Scientific Council of the AFM-Telethon and additional international experts. An opening at the international level to accelerate the development of innovative treatments to cure the sick and keep commitments to donors.
Illustration for article: Rare diseases : 38 million Euro funding for research

Rare diseases : 38 million Euro funding for research

European Union has announced 38 million Euro funding for research towards new treatments and for the development of IRDiRC, the central global rare disease hub involving 70 institutions – including AFM-Telethon.
Illustration for article: Telethon 2012: 81,065,239€. Thank you for having met the challenge

Telethon 2012: 81,065,239€. Thank you for having met the challenge

This year’s Telethon will remain the challenge of all challenges: the challenge of donors and volunteers in the face of crisis, the challenge of researchers and families in the face of disease ... Together, we have tackled them, with determination and courage, all united by the same desire: win!
Illustration for article: Telethon 2012 : "Dare to win"

Telethon 2012 : "Dare to win"

“Dare to win” is the campaign slogan for the Telethon 2012. It is also the families’ cry of hope that will be launched to the French public on December 7th and 8th.
Illustration for article: Telethon 2012 : New drug trials in 2013

Telethon 2012 : New drug trials in 2013

Young patients with immunodeficiencies, rare diseases of the blood and brain, have already benefited from innovative therapies stemming from research driven by the Telethon. Thirty-six trials are in progress or in preparation for nearly 30 diseases.
Illustration for article: AFM-Telethon to be the first non-profit stakeholder in the world of medicine

AFM-Telethon to be the first non-profit stakeholder in the world of medicine

A few days before the launch of the Telethon on December 7th and 8th , the AFM-Telethon organised a press conference in Paris, presenting the Association’s challenges for 2013 and the researchers that it supports.
Illustration for article: The AFM-Telethon has been rewarded for its transparent and responsible communication

The AFM-Telethon has been rewarded for its transparent and responsible communication

At the ceremony of the 26th Communication and Entreprise awards 2012, the AFM-Telethon received the responsible communication award and a distinction for its 2011 Annual Report.
Illustration for article: Shinya Yamanaka, 2012 Nobel Prize in Medicine visits the I-Stem laboratory

Shinya Yamanaka, 2012 Nobel Prize in Medicine visits the I-Stem laboratory

On Friday November 9th, the Japanese physician and researcher, Shinya Yamanaka, who was awarded the Nobel Prize in Medicine on October 8th for his work on IPS cells (Induced Pluripotent Stem cells), visited the I-Stem laboratory in Evry.
Illustration for article: Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!

Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!

With this decree, Genethon will be able to accelerate the production of gene therapy for human trials through its center, Genethon Bioprod, which has the largest capacity in the world in this field.
Illustration for article: Généthon receives the 2012 French Galien Prize

Généthon receives the 2012 French Galien Prize

Généthon receives the 2012 French Galien Prize for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy and gene therapy.”
Illustration for article: The Biotherapies Institute, a unique and exceptional task force

The Biotherapies Institute, a unique and exceptional task force

Launched in 2012, the Biotherapies Institute gathers the expertise of existing laboratories to accelerate and manage the development of innovative treatments for rare diseases.
Illustration for article: Call for proposals ends on Septembre 28th

Call for proposals ends on Septembre 28th

AFM-Telethon will support research projects from both French and foreign groups. Proposals aim to support fundamental research on neuromuscular system, develop therapeutic approach and improve care management of patient.
Illustration for article: SMA Europe: calls for 2012

SMA Europe: calls for 2012

SMA Europe is pleased to announce its 5th international Call for SMA Research Projects. This new Call for SMA Projects will be open to any research project aimed at finding a therapy for Spinal Muscular Atrophy (SMA).
Illustration for article: 1st european appoval for a gene therapy drug

1st european appoval for a gene therapy drug

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended, last Friday, the authorisation of Glybera (alipogene tiparvovec) for marketing in the European Union. For Fulvio Mavilio, Genethon CSO, that’s “great news for the gene therapy field".
Illustration for article: Alain Schwenck becomes Director of Genethon Bioprod

Alain Schwenck becomes Director of Genethon Bioprod

Since April 2nd, Alain Schwenck, 51, is the new director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon.
Illustration for article: 94 091 902 euros: increase of donations thanks to an exceptional mobilization

94 091 902 euros: increase of donations thanks to an exceptional mobilization

Telethon’s donations for 2011 have reached over 94 million euro. It is a 4% increase compared to 2010’s donations. This is the result of an exceptional mobilization.
Illustration for article: French Telethon 2013 results: 78 341 598 euros

French Telethon 2013 results: 78 341 598 euros

This new edition show us how Téléthon is a social link, a fantastic solidarity, a sort of confidence pact between all of the Téléthon vital forces.
Illustration for article: Fulvio Mavilio, expert in gene therapy for rare diseases, Généthon's new Scientific Director

Fulvio Mavilio, expert in gene therapy for rare diseases, Généthon's new Scientific Director

Fulvio Mavilio, PhD (aged 58), an international acknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) with donations from France's annual Telethon) on January 1st, 2012.
Illustration for article: Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012.